BVS vs. WRBY, LIVN, ENOV, NVCR, TMDX, LMAT, TNDM, SLNO, CNMD, and CDRE
Should you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include Warby Parker (WRBY), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), TransMedics Group (TMDX), LeMaitre Vascular (LMAT), Tandem Diabetes Care (TNDM), Soleno Therapeutics (SLNO), CONMED (CNMD), and Cadre (CDRE). These companies are all part of the "medical equipment" industry.
Bioventus vs.
Bioventus (NYSE:BVS) and Warby Parker (NYSE:WRBY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, community ranking, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.
In the previous week, Warby Parker had 3 more articles in the media than Bioventus. MarketBeat recorded 9 mentions for Warby Parker and 6 mentions for Bioventus. Bioventus' average media sentiment score of 0.70 beat Warby Parker's score of 0.54 indicating that Bioventus is being referred to more favorably in the media.
Warby Parker has a net margin of -4.39% compared to Bioventus' net margin of -7.11%. Bioventus' return on equity of 15.61% beat Warby Parker's return on equity.
Bioventus has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Warby Parker has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500.
Bioventus presently has a consensus price target of $15.00, indicating a potential upside of 49.85%. Warby Parker has a consensus price target of $21.92, indicating a potential downside of 8.76%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than Warby Parker.
Warby Parker received 10 more outperform votes than Bioventus when rated by MarketBeat users. However, 62.50% of users gave Bioventus an outperform vote while only 42.11% of users gave Warby Parker an outperform vote.
62.9% of Bioventus shares are held by institutional investors. Comparatively, 93.2% of Warby Parker shares are held by institutional investors. 32.9% of Bioventus shares are held by company insiders. Comparatively, 26.6% of Warby Parker shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Warby Parker has higher revenue and earnings than Bioventus. Warby Parker is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.
Summary
Warby Parker beats Bioventus on 10 of the 18 factors compared between the two stocks.
Get Bioventus News Delivered to You Automatically
Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bioventus Competitors List
Related Companies and Tools
This page (NYSE:BVS) was last updated on 2/22/2025 by MarketBeat.com Staff
